Research Square
June 17, 2026
Tanya Dudinskaya, Miliaikeala Heen, Joel Lieberman et al.
preprint
Abstract Objectives Law enforcement officers (LEOs) experience chronic occupational stressors linked to psychological and physiological challenges, with limited research on social health impacts. The purpose of the current study was to investigate the effects of the pilot Mindfulness-Based Resilience Training for First Responders (MBRT-FR) on LEOs’ psychological, physiological, and social...
ACS Chemical Neuroscience
June 17, 2026
Anoushka Bhat, Elmira Zolali, Mahfuz A Sakib et al.
Psychedelics have re-emerged as promising therapeutics for neuropsychiatric disorders, including depression, anxiety, post-traumatic stress disorder, and substance use disorders. While their beneficial effects are largely attributed to serotonin 2A (5-HT2A) receptor activation, psychedelics exhibit substantial diversity in chemical structure, receptor binding kinetics, metabolism, and duration...
Research Square
June 17, 2026
Martijn Arns, Kenneth Shinozuka, Joseph P Barsuglia
preprint
Abstract Ibogaine has shown early therapeutic promise for substance use disorders (SUD) and post-traumatic stress disorder in veterans, but concerns about treatment-associated cardiac arrhythmia and death have constrained clinical development. Whether this risk is uniform across indications or concentrated in specific populations is unknown. We conducted a retrospective multisite study of...
Frontiers in Public Health
June 17, 2026
Lawrence Leeman, Maya Armstrong, Dara Menashi et al.
Informed by a community engagement process, we have developed a pragmatic, open-label, hybrid feasibility-implementation study of Group Psilocybin-Assisted Therapy (GPAT) for post-traumatic stress disorder (PTSD). As psychedelic-assisted therapies begin to enter the broader mental health arena, engaging communities in the design of research and care models is essential to ensuring that those...
SAIMSARA Journal
June 15, 2026
This scoping review aims to comprehensively map and synthesize the breadth of evidence from original research on the relationship between psilocybin and health, spanning clinical trials, epidemiological surveys, mechanistic experiments, and cross-sectional attitudinal studies. The review uses 145 references and builds its evidence map from 216 original studies with 271241797 total...
Journal of Clinical Psychology
June 15, 2026
Lucas Cruz, Fernando R. Beserra, Julia M.k. Freind et al.
Recent studies have shown promising results for psychedelics in the treatment of psychiatric disorders. Both in clinical and recreational settings, contextual elements, such as music, can influence the experience of users and may be linked to positive outcomes. This systematic review identifies how music is being selected and used in psychedelisc-assisted psychotherapy (PAP). The search adopted...
Molecular Psychiatry
June 11, 2026
Ritchy Hodebourg, Lillian Duncan, Eric Dereschewitz et al.
The rising legal acceptance of cannabis and the high comorbidity between cannabis use disorder (CUD) and post-traumatic stress disorder (PTSD) highlight the importance of understanding how stress and cannabis influence the brain. We recently discovered that cannabinoid use promotes two PTSD-like symptoms: avoidance coping behaviors and the generalization of stress-coping responses to a neutral...
Journal of Surgery and Medicine
June 11, 2026
Davon Lee, Elizabeth Beyene, Da’Jhai Monroe et al.
Background/Aim: Ketamine is frequently administered for analgesia and sedation during burn dressing changes, but its potential psychological impact remains a concern. This study assessed whether ketamine exposure during early burn care is associated with subsequent depression, acute stress reaction (ASR), or post-traumatic stress disorder (PTSD) in patients with major burns. Methods: A...
Journal of Affective Disorders Reports
June 8, 2026
Marzieh Jalalian-Javadpour, Batool Ghorbani Yekta, Niloufar Reyhani et al.
Psilocybin is a chemical compound found in certain types of hallucinogenic mushrooms, known as magic mushrooms. Evidence has shown potential therapeutic effects of psilocybin on different neuropsychiatric disorders such as major depressive disorder (MDD), posttraumatic stress disorder (PTSD), anxiety disorders, and obsessive-compulsive disorder (OCD). Although the efficacy of psilocybin in...
Neuropharmacology
June 6, 2026
Devin P Hagarty, Adam Dawoud, Alfonso Brea Guerrero et al.
Ketamine, a non-competitive N-Methyl-D-Aspartate receptor antagonist, was approved for use with Treatment-Resistant Depression (TRD) and is currently in clinical trials for treating substance use disorder (SUD), and Post Traumatic Stress Disorder. However, ketamine is an addictive drug, and thus we need to better understand ketamine's mechanism of action in addiction to reliably assess the...